SCHEMBL7511020

SCHEMBL7511020

N#Cc1ccc2[nH]c(-c3ccc(/C=C4/SC(=O)NC4=O)cc3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
ESRRA P11474 7/20 0.47
RHEB Q15382 1/20 0.46
ESRRB O95718 1/20 0.44
ESR1 P03372 1/20 0.44
ESRRG P62508 1/20 0.44
ESR2 Q92731 1/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CG P48736 2/20 0.44
CISD1 Q9NZ45 3/20 0.44
MAOB P27338 2/20 0.44
RAB9A P51151 2/20 0.44
PKN1 Q16512 1/20 0.44
PKN2 Q16513 1/20 0.44
PIK3CD O00329 1/20 0.44
NPC1 O15118 1/20 0.44
CSNK2A2 P19784 1/20 0.44
PIK3CB P42338 1/20 0.44
MTOR P42345 1/20 0.44
CLK1 P49759 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7511024 1.00 TDP1 (0.47) TDP1ESRRARHEBESRRBESR1
SCHEMBL7511028 0.91 PKN1 (0.55) TDP1ESRRARHEBESRRBESR1
SCHEMBL7521926 0.80 PIM1 (0.60) ESRRACISD1PIM1PIM2
SCHEMBL7521930 0.80 PIM1 (0.60) ESRRACISD1PIM1PIM2
SCHEMBL7511827 0.80 PIM1 (0.56) TDP1CISD1MAOBRAB9APKN1
SCHEMBL7511829 0.80 PIM1 (0.56) TDP1CISD1MAOBRAB9APKN1
SCHEMBL7516143 0.80 PIM1 (0.51) TDP1PIK3CAPIK3CGCISD1MAOB
SCHEMBL7511802 0.80 PIM1 (0.51) TDP1PIK3CAPIK3CGCISD1MAOB
SCHEMBL7511794 0.80 PIM1 (0.51) TDP1PIK3CAPIK3CGCISD1MAOB
SCHEMBL7516149 0.80 PIM1 (0.51) TDP1PIK3CAPIK3CGCISD1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 TDP1 17/4885ESRRA 917/4885RHEB 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.